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Background: Cancer cells engage in aerobic glycolysis and glutaminolysis to fulfill their biosynthetic and energetic
demands in part by activating MYC. Previous reports have characterized metabolic changes in proliferating cells
upon MYC loss or gain of function. However, metabolic differences between MYC-dependent cancer cells and their
isogenic differentiated counterparts have not been characterized upon MYC suppression in vitro.
Results: Here we report metabolic changes between MYC-dependent mouse osteogenic sarcomas and
differentiated osteoid cells induced upon MYC suppression. While osteogenic sarcoma cells increased oxygen
consumption and spare respiratory capacity upon MYC suppression, they displayed minimal changes in glucose and
glutamine consumption as well as their respective contribution to the citrate pool. However, glutamine significantly
induced oxygen consumption in the presence of MYC which was dependent on aminotransferases. Furthermore,
inhibition of aminotransferases selectively diminished cell proliferation and survival of osteogenic sarcoma MYC-
expressing cells. There were minimal changes in ROS levels and cell death sensitivity to reactive oxygen species
(ROS)-inducing agents between osteoid cells and osteogenic sarcoma cells. Nevertheless, the
mitochondrial-targeted antioxidant Mito-Vitamin E still diminished proliferation of MYC-dependent osteogenic
sarcoma cells.
Conclusion: These data highlight that aminotransferases and mitochondrial ROS might be attractive targets for
cancer therapy in MYC-driven tumors.
Keywords: MYC, Glutaminolysis, Glucose, Glutamine, Oncogene addiction, Mitochondrial ROS, Mitochondrial
metabolismFindings
Background
Tumor cells display increased glucose metabolism to
meet the anabolic demands required for cell prolifera-
tion [1]. Glycolytic intermediates fuel anabolic pathways
that synthesize NADPH, ribose, phospholipids, triacyl-
glycerols, and serine [2]. However, aerobic glycolysis by
itself is not able to supply all the metabolites required
for cell proliferation. The mitochondrial tricarboxylic
acid cycle (TCA cycle) provides additional metabolites
that funnel into lipid, amino acid and nucleotide synthe-
sis. TCA cycle-dependent biosynthesis requires constant
replenishment of carbons into the TCA via multiple ana-
plerotic pathways [3]. Pyruvate derived from glucose can* Correspondence: nav@northwestern.edu
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reproduction in any medium, provided the orprovide acetyl-CoA and oxaloacetate to initiate the TCA
while glutamine can also replenish the TCA metabolites
through the process of glutaminolysis, where glutamine
is converted to glutamate by glutaminases (GLSs), which
then enters the TCA cycle by conversion into alpha-
ketoglutarate by the aminotransferases or glutamate
dehydrogenase [4]. Additionally, glutamine serves as an
important nitrogen donor for assembly of amino acids,
nucleotides and nicotinamide. Collectively, the metabo-
lism of glucose and glutamine can provide nearly all the
necessary carbon and nitrogen required for optimal cell
proliferation and growth.
In the past decade, there have been multiple mechanisms
uncovered that regulate the metabolism of glucose and
glutamine for cell proliferation in normal and cancer cells
[5,6]. One mechanism, by which both normal and cancer
cells meet their metabolic demands for cell proliferation, is
through activation of c-MYC (herein termed MYC) [7].d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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dependent signaling to stimulate aerobic glycolysis
and glutaminolysis to promote cell proliferation, while
cancer cells have deregulated MYC allowing proliferation
to occur in a cell-autonomous manner [8,9]. For example,
MYC increases glycolysis in part through the regulation of
lactate dehydrogenase A (LDHA) and glutaminolysis by
upregulating expression of GLS [10-12]. MYC also regu-
lates mitochondrial metabolism through induction of
genes such as TFAM, which is required for replication and
maintenance of mitochondrial DNA and mitochondrial
biogenesis [13]. A consequence of increased mitochondrial
metabolism is the generation of reactive oxygen species
(ROS) that are required to drive tumorigenesis [14,15].
Much of our understanding of MYC has come from
examining metabolic pathways required for cell prolifera-
tion upon MYC loss or gain of function [12,13,16]. In the
current study we took the opposite approach - whereby
metabolic changes were examined when MYC was
suppressed in osteosarcoma cells highly dependent on
MYC for their tumorigenic potential [17]. MYC suppres-
sion in these genetically engineered mouse osteosarcoma
cells results in differentiation into osteocytes. This allowed
us to compare metabolic differences between differentiated
and proliferating cells of the same genetic background.
Our results indicate the induction of glutaminolysis as the
major metabolic difference observed between MYC-
dependent osteosarcoma cells and osteocytes. Further-
more, mitochondrial-targeted antioxidants diminished
proliferative capacity of osteosarcoma cells without
having detrimental effects on osteocytes.
Methods
Cell culture and reagents
MYC-dependent osteogenic sarcoma cells were isolated
from a transgenic mouse as previously described [17].
These cells in the presence of doxycycline undergo differen-
tiation into osteocytes. Osteosarcoma cells were cultured in
high glucose Dulbecco’s modification of Eagle’s medium
(DMEM) supplemented with 5% penicillin/streptomycin,
10% fetal bovine serum (FBS) and HEPES buffer. For nut-
rient deprivation experiments, glucose and glutamine-free
DMEM was supplemented with 10% dialyzed serum in
the presence of 10 mM glucose and/or 4 mM gluta-
mine. Rotenone, antimycin A, oligomycin, FCCP, ami-
nooxyacetic acid (AOA), N-acetylcysteine (NAC),
beta-phenylethyl isothiocyanate (PIETC) and buthio-
nine sulfoximine (BSO) were purchased from Sigma
(St. Louis, MO, USA). Antibodies against MYC and
actin were purchased from Santa Cruz Biotechnology
(Santa Cruz, CA, USA). Antibodies against VDAC1, GOT2
and GPT2 were purchased from Abcam (Cambridge, MA,
USA). Antibody against GLS1 was prepared in the
Matés laboratory.Oxygen consumption rate
Oxygen consumption rate (OCR) was measured using
the 24 well Extracellular Flux Analyzer XF24 (Seahorse
Bioscience, North Billerica, MA, USA) according to the
manufacturer’s protocol. Cells were equilibrated with
DMEM lacking bicarbonate and HEPES at 37°C for one
hour in an incubator lacking CO2. Basal OCR was mea-
sured followed by sequential treatments with oligomycin
A (5 μM), carbonyl cyanide 4-(trifluoromethoxy)phenyl-
hydrazone (FCCP, 10 μM) and antimycin A (2 μM) +
rotenone (2 μM). Measurements were normalized to
cell number in each well. A minimum of four wells
were utilized per condition in any given experiment. The
spare respiratory capacity was calculated as previously
described [18].
ROS measurement
Mitochondrial ROS production was measured using a
redox sensitive GFP probe (roGFP2) targeted to the mito-
chondrial matrix or cytosolic compartments. Cells were
infected with adenovirus containing roGFP2 as previously
described [19]. As internal controls, samples were fully
reduced with 1 mM dithiothreitol (DTT) and fully oxi-
dized with 1 mM H2O2. Upon oxidation the roGFP2 gains
excitability at 405 nm while losing excitability at 488 nm.
Percent oxidized probe was determined with the equation:
(R-RDTT)/(R-RH2O2)
where R is sample without DTT or H2O2 added; RDTT
fully reduced sample, and RH2O2 is fully oxidized.
Cell cycle analysis and death
Cells were trypsinized and fixed in ethanol 70% overnight
at −20°C. Subsequently, cells were resuspended in a PBS
solution containing 50 μg/mL propidium iodide (PI) and
0.1 mg/mL RNase A and incubated 40 minutes at 37°C.
Then, the cell pellet was resuspended in PBS and analyzed
using a FACS flow-cytometer (Becton Dickinson, Franklin
Lakes, NJ USA). Cell death was determined by incubating
cells in 0.1 μg/mL PI. Data were analyzed with CellQuest
software.
Mitochondrial membrane potential
Cells were stained with 100 nM tetramethylrhodamine,
ethyl ester (TMRE) for 30 minutes in PBS at 37°C. The
cells were trypsinized and washed with PBS. As control,
cells were treated with the uncoupling agent FCCP at
50 μM for 10 minutes before staining. Median fluorescence
intensity (MFI) values were corrected by FCCP background
in each cell type. Data were analyzed in a Beckton
Dickinson LSR Fortessa cell analyzer (Franklin Lakes,
NJ USA and analyzed with FlowJo (Ashland, OR,
USA) software.
Anso et al. Cancer & Metabolism 2013, 1:7 Page 3 of 10
http://www.cancerandmetabolism.com//1/1/7Metabolic assays
Concentrations of glucose, lactate, and glutamine were
determined by incubating cells in DMEM with 10%
dialyzed FBS and supplemented with 10 mM D-glucose
and 2 mM L-glutamine. After six hours, 0.6 mL aliquots
of medium were analyzed using an automated electro-
chemical analyzer (BioProfile Basic-4 analyzer; NOVA
Biomedical, Waltham, MA, USA). Metabolic rates were
determined by normalizing absolute changes in metabolite
abundances to protein content as previously described
[20]. Isotopic labeling was performed in DMEM with 10%
dialyzed FBS supplemented with either 10 mM D-[U-13C]
glucose and 2 mM L-glutamine, or 2 mM L-[U-13C]
glutamine and 10 mM D-glucose. After six hours,
metabolites were extracted with 50% methanol and
analyzed using an Agilent 6970 gas chromatograph
and an Agilent 5973 (Santa Clara CA, USA) mass
selective detector. Analysis of 13C enrichment and
mass isotopomer distribution was performed as previously
described [21].
Statistical analysis
P-values associated with all pairwise comparisons were
based on Student’s t-test for independent groups. Error
bars were defined using standard error of the mean (SEM).
Results and discussion
Osteogenic sarcoma cells differentiate into osteocytes upon
MYC suppression
Previous reports have utilized inducible systems to








Figure 1 Osteogenic sarcoma cells differentiate into mature osteocyt
sarcoma cells treated with doxycycline (20 ng/mL) at 24, 48, 72 and 96 hou
after 24 and 48 hours treatment with doxycycline (20 ng/mL). (c) Cell cycle
(PI) after 48 hours doxycycline (20ng/ml) treatment. N = 4 ± SEM * P < 0.05inducible systems in immortalized proliferating cells
[13]. We were interested in using a conditional system
examining metabolic differences upon MYC suppression
in a tumor cell background. This would permit us to
characterize, in a unique system, the metabolic
differences between cancer cells and their isogenic
differentiated counterparts. Previously, an inducible
MYC-dependent mouse osteogenic sarcoma cell line was
characterized, which upon doxycycline treatment, becomes
a differentiated osteocyte [17]. We also find that these
mouse osteosarcoma cells, upon suppression of their MYC
protein levels, display morphological changes and an inhi-
bition of proliferation consistent with a differentiation
phenotype (Figure 1).
Osteocytes have increased mitochondrial oxygen
consumption compared to MYC-dependent osteogenic
sarcoma cells
Previous reports indicate that MYC induction can stimu-
late oxygen consumption [13]. However, these studies
compared metabolic differences between proliferating
cells with or without MYC. We calculated basal mito-
chondrial respiration by measuring oxygen consumption
and subtracting the residual oxygen consumption in the
presence of electron transport complex I and III inhibi-
tors rotenone and antimycin, respectively (Figure 2a).
Coupled respiration indicates the rate of mitochondrial
oxygen consumption utilized to generate ATP by the
mitochondrial F1Fo-ATPase (Figure 2a). The basal
respiration subtracted from the residual respiration upon
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Figure 2 Bioenergetic profiles of osteocytes and MYC-dependent osteogenic sarcoma cells. (a) Oxygen consumption rate (OCR) was
determined using a Seahorse Bioscience XF24 Flux Analyzer by sequential injection of oligomycin, FCCP and antimycin A/rotenone. (b) Basal,
coupled, maximal, and uncoupled oxygen consumption rate (OCR) was assessed in osteogenic sarcoma cells in the presence or absence of 20
ng/mL doxycycline for 48 hours. N = 6 ± SEM * P < 0.05 compared to 0 ng/ml doxycycline. (c) Spare respiratory capacity defined as maximal
respiration minus basal respiration. N = 6 ± SEM * P < 0.05 compared to 0 ng/ml doxycycline. (d) Mitochondrial membrane potential as assessed
by TMRE mean fluorescence intensity (MFI), corrected by FCCP. N = 5 ± SEM * P<0.05 compared to 0 ng/ml doxycycline.
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Maximal respiration can be calculated by the addition of
FCCP, a potent protonophore which uncouples mito-
chondrial ATP generation from oxygen consumption
(Figure 2a). Osteocytes displayed an increase in coupled
and maximal respiration compared to osteogenic
sarcoma cells (Figure 2b). The spare respiratory capacity,
a measure of how effectively the electron transport chain
can respond to energy demand, was also substantially
elevated in osteocytes compared to osteogenic sarcoma
cells (Figure 2c). Mitochondrial membrane potential is
another measure of mitochondrial fitness. Mitochondrial
membrane potential allows efficient import and export of
proteins to the mitochondrial matrix. Mitochondria that
lose their membrane potential undergo mitophagy. We
utilized the TMRE fluorescent dye to assess mitochondrial
membrane potential and subtracted the fluorescence upon
the addition of FCCP, which dissipates the mitochondrial
membrane potential. Osteocytes had a substantial increase
in mitochondrial membrane potential compared to
MYC-dependent osteogenic sarcoma cells (Figure 2d).
These data indicate that, overall, differentiated osteocytes
have better bioenergetic capacity than MYC-dependent
osteogenic sarcoma cells.Glucose and glutamine stimulate glycolysis and respiration
respectively in MYC-dependent osteogenic sarcoma cells
MYC-dependent osteogenic sarcoma cells displayed a
slight elevation in glucose consumption and lactate pro-
duction compared with osteocytes (Figure 3a). Although
there was no change in overall glutamine consumption be-
tween osteogenic sarcoma cells and osteocytes (Figure 3a),
glutamine substantially stimulated OCR in osteogenic sar-
coma cells compared to osteocytes (Figure 3b), suggesting
an impairment of entry of glutamine-derived carbon into
the TCA cycle when MYC expression was curtailed. We
incubated cells without glutamine for one hour and subse-
quently measured basal respiration followed by addition of
glutamine. MYC increases cell proliferation in osteogenic
sarcoma cells, thereby placing a heavy demand for mito-
chondrial TCA cycle metabolites for macromolecule
synthesis. In particular, citrate is exported from the mito-
chondria and utilized for fatty acid synthesis in MYC-
dependent cancer cells. Glutamine fuels mitochondria
through the process of glutaminolysis, where carbons from
glutamine enter the citric acid cycle through conversion to
glutamate, and subsequently to alpha-ketoglutarate. The
alpha-ketoglutarate undergoes decarboxylation by alpha-
ketoglutarate dehydrogenase to eventually regenerate
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Figure 3 Glucose and glutamine-dependent metabolism in osteocytes and MYC- dependent osteogenic sarcoma cells. Doxycycline
(20 ng/mL) was added to MYC- dependent osteogenic sarcoma cells and incubated for 48 hours. (a) Glucose and glutamine consumption
along with lactate production was measured at six hours. N = 3 ± SEM * P<0.05 compared to 0 ng/ml doxycycline. (b) Cells were incubated
in glutamine-free media for one hour. OCR was determined by injection of glutamine (4 mM). N = 5 ± SEM * P<0.05 compared to 20 ng/ml
doxycycline. (c) Glucose and glutamine carbons feed into the TCA cycle. (d) and (e) Doxycycline was added to cells (0 or 20 ng/mL) and
incubated for 48 hours and then labeled for six hours with either U13-Glucose or U13-Glutamine and subsequently citrate pools were examined.
N = 3 ± SEM * P<0.05 compared to 0 ng/ml doxycycline.
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reducing equivalents NADH and FADH2, both of which
donate electrons to the mitochondrial respiratory chain
and consequently drive oxygen consumption (Figure 3c).
Oxaloacetate combines with acetyl-CoA to generate citrate,
initiating another round of oxidative metabolism to gene-
rate precursors for the synthesis of lipids and other macro-
molecules. Because many nutrients, including glucose and
glutamine, can supply acetyl-CoA and/or oxaloacetate, we
performed 13C tracing experiments to define the specific
contribution of glucose and glutamine to these pools.
When cells were cultured with [U-13C]-glucose and un-
labeled glutamine for six hours, the osteocytes displayed a
significant increase in the unlabeled citrate fraction (m+0)
and a decrease in glucose derived m+2, m+4, and m+6
pools indicating that over this time period, a lower fraction
of the citrate pool was supplied by glucose metabolism. To
examine the effect of MYC suppression on glutamine’s
contribution to citrate formation, we cultured both celllines with [U-13C]-glutamine and unlabeled glucose and
examined 13C enrichment in citrate. Citrate m+4 is formed
when glutamine-derived alpha-ketoglutarate is metabolized
in the TCA cycle to generate OAA m+4; this can combine
with an unlabeled acetyl-CoA to form citrate with four
additional mass units. We observed a modest increase in
the unlabeled fraction, and a decrease in the amount of
glutamine-derived citrate m+4 in the osteocytes (Figure 3e).
Interestingly, there was an increase in glutamine-derived
citrate m+5 when MYC was suppressed. This suggests that
osteocytes engage in glutamine-dependent reductive carb-
oxylation, a phenomenon observed in brown fat, cancer
cells with defective mitochondria or under hypoxia [21-24].
This is consistent with the higher ability of glutamine to
activate respiration in MYC-expressing cells (Figure 3b).
Glutamine-induced respiration is likely a combined
result of reducing equivalents generated during the
conversion of glutamine to OAA for anaplerosis, plus
the enhanced entry of 13C-labeled, glucose-derived
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expressed (Figure 3d). Osteocytes, which do not engage
in proliferation, may use glutamine for other processes
in addition to anaplerosis.
MYC-dependent osteogenic sarcoma cells are dependent on
glucose and glutamine compared to osteocytes
Previous data indicate that MYC-dependent cancer
cells are dependent on glucose and glutamine for pro-
liferation and survival [25]. In agreement with these
previous studies, we observed that osteogenic sarcoma
cells underwent a substantial decrease in cell prolif-
eration and increase in cell death upon glucose or
glutamine deprivation (Figure 4a and 4b). By contrast,
MYC-deprived osteocytes displayed a slight increase































 Dox 0 ng/ml
 Dox 20 ng/ml
Glucose (10 mM)
Glutamine (4 mM) - +          - + 





















Glucose (10 mM) +     +      -

















 DMK 5 mM
 NAC 1 mM
 DMK/NAC
Dox (ng/ml) 0












Figure 4 MYC-dependent osteogenic sarcoma cells are dependent on
added to MYC-dependent osteogenic sarcoma cells and incubated for 48 h
depleted of glucose, glutamine or both. (a) Cell death was assessed after 4
glucose and glutamine. (b) Cell number was assessed after 24 hours. N = 3
glutamine. (c) Cytosolic ROS was measured after 24 hours using roGFP2. N
and glutamine. (d) Cell death was assessed in osteogenic sarcoma cells de
pyruvate (5 mM) and/or NAC (1 mM). N = 3 ± SEM * P < 0.05 compared to
assessed in osteogenic sarcoma cells depleted with glutamine and supplem
compared to media containing no glucose and no glutamine. (f) Cell cycle
treated with DMK and doxycycline. N = 3 ± SEM * P < 0.05 compared to 0
osteogenic sarcoma cells treated with DMK (0–5 mM), glutamine (4 mM) a(Figure 4a). To understand the mechanism underlying
the induction of cell death upon glucose or glutamine
deprivation in MYC-dependent osteogenic sarcoma cells,
we examined the levels of ROS, which can induce cell
death at high levels. One of the primary mechanisms by
which cells regulate ROS levels is through detoxification
by glutathione. However, NADPH is required to maintain
this redox balance by reducing oxidized glutathione.
Importantly, glucose and glutamine catabolism support
NADPH production through pentose phosphate pathway
and glutaminolysis, respectively. Thus, the deprivation of
these nutrients could increase ROS levels, contributing to
the increase in cell death. Indeed, osteogenic sarcoma cells
starved for glucose or glutamine induced a dramatic in-
crease in the oxidation of cytosolic redox-sensitive GFP
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8 hours. N = 3 ± SEM * P < 0.05 compared to media containing both
± SEM * P < 0.05 compared to media containing both glucose and
= 4 ± SEM * P < 0.05 compared to media containing both glucose
pleted with glutamine and supplemented with galactose (10 mM),
media containing both glucose and glutamine. (e) Cell death was
ented with DMK (5 mM) and/or NAC (1 mM). N = 4 ± SEM * P < 0.05
analysis at 48 hours in osteogenic sarcoma cells simultaneously
ng/ml doxycycline. (g) Phase contrast microscopy pictures of
nd doxycycline.
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for this increase in cell death, we administered the antioxi-
dant NAC upon glucose or glutamine deprivation. How-
ever, NAC did not prevent cell death due to glucose
deprivation (Figure 4d). Interestingly galactose, which
mainly supports cell proliferation by entering into the
pentose phosphate pathway and makes cells exclu-
sively rely on oxidative phosphorylation for ATP gen-
eration [26], could not substitute glucose (Figure 4d).
This is in contrast to oncogenic Kras-driven tumor
cells which can rely on galactose [14]. Also, NAC did
not diminish cell death upon glutamine deprivation.
However, NAC in combination with cell-permeable di-
methyl alpha-ketoglutarate (DMK) diminished cell death
(Figure 4e). DMK in the presence of glutamine did not
prevent cell cycle arrest upon doxycycline adminis-
tration, suggesting that providing the end product of
glutaminolysis is not sufficient to prevent cell cycle
arrest that accompanies the transition of MYC-
dependent osteogenic sarcoma cells into osteocytes
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Figure 5 MYC-dependent osteogenic sarcoma cells are dependent on
dependent osteogenic sarcoma cells and incubated for 48 hours. (a) Cells
and subsequently after the addition of glutamine (4 mM) followed by AOA
glutamine. (b) Protein expression of GLS1, GPT2, and GOT2 in mitochondri
and tubulin are loading controls for mitochondrial and cytosolic fractions, r
with AOA (1 mM). N = 3 ± SEM * P < 0.05 compared to 0 mM DMK with 1
AOA (1 mM) in the presence of DMK (0–5 mM). N = 6 (control condition) a
0 mM AOA.MYC-dependent osteogenic sarcoma cells are dependent on
aminotransferases
In MYC-overexpressing cells glutaminase is upregulated,
favoring the conversion of glutamine to glutamate. Sub-
sequently, aminotransferases or glutamate dehydrogen-
ase (GDH) convert glutamate into alpha-ketoglutarate to
fuel the TCA cycle. To test whether aminotransferases
are required for glutamine-dependent increase in OCR
in MYC-dependent osteogenic sarcoma cells, we utilized
AOA, an inhibitor of aminotransferase activity. Glutam-
ine substantially stimulated OCR which was diminished
by AOA and rescued by DMK (Figure 5a). Interestingly,
GLS1 protein levels in the mitochondrial fractions
did not change upon doxycycline addition while the
protein levels of the aminotransferase GOT2 in the
mitochondrial fractions substantially diminished.
GPT2, the other aminotransferase in the mitochon-
dria, slightly diminished upon doxycycline addition
(Figure 5b). AOA induced cell death and decreased cell
proliferation, which was rescued by DMK in the MYC-
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Figure 6 MYC-dependent osteogenic sarcoma cells are dependent on mitochondrial ROS for cell proliferation. Doxycycline (20 ng/mL)
was added to MYC-dependent osteogenic sarcoma cells and incubated for 48 hours. (a) Mitochondrial ROS was assessed using oxidation of
mitochondrial targeted roGFP2. N = 4 ± SEM * P<0.05 compared to without doxycycline. (b) Cytosolic ROS was assessed using oxidation of
cytosolic roGFP2. N = 4 ± SEM. (c) Cells were treated with PEITC (0 to 100 μM) for 24 hours and cell death was measured. N = 4 ± SEM. (d) Cells
were treated with BSO (0 to 100 uM) for 24 hours and cell death was measured. N = 4 ± SEM (e) Mitochondrial ROS as assessed by mito-roGFP2
in cells treated with control TPP (0.5 μM) or mitochondrial targeted vitamin E (MVE 0.5 μM). N = 6 ± SEM * P<0.05 compared to TPP control. (f)
Cell proliferation was assessed upon treatment with TPP (1 μM) or MVE (0.5 or 1 μM) for 48 and 72 hours. N = 3 ± SEM * P<0.05 compared to 1
mM TPP control. (g) Cell death was assessed after 48 hours of treatment with TPP or MVE. N = 4 ± SEM * P<0.05 compared to 1 mM TPP control
without doxycycline.
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differentiated osteocytes (Figure 5a and 5d). Collectively,
these results indicate that MYC-dependent cancer cells
have an increased dependence on aminotransferases when
compared to their isogenic differentiated counterparts.
MYC-addicted osteogenic sarcoma cells are dependent on
mitochondrial ROS for cell proliferation
Previously, we and others have demonstrated thatMYC or
oncogenic Ras-dependent cancer cells have higher levels
of ROS compared to their isogenic immortalized cells
[14,27,28]. At low levels ROS can be utilized to activate
signaling pathways such as AKT and mitogen-activated
protein (MAP) kinases to provide necessary proliferative,
growth and survival signals for tumorigenesis. Further-
more, ROS can activate transcription factors such as
nuclear factor kappa beta (NF-KB) and hypoxia inducible
factors (HIFs) which are important for metabolicadaptation and survival. Antioxidants which decrease
ROS levels can prevent MYC-dependent tumorigenesis in
part by inhibiting HIFs [29]. By contrast, increasing ROS
levels through various mechanisms including inhibiting
glutathione synthesis, selectively induces cancer cell death
since cancer cells have higher basal levels of ROS com-
pared to normal cells. We analyzed cytosolic ROS and
mitochondrial ROS levels with a cytosolic-targeted
roGFP2 probe and a mitochondrial-targeted roGFP2
(mito-roGFP2) in MYC-dependent osteogenic sarcoma
cells and osteocytes. This redox-sensitive GFP probe
contains two reactive cysteine thiols located on the outer
surface. Hydrogen peroxide can oxidize these thiols while
DTT can reduce these thiols. roGFP2 emission at 525 nm
is assessed via flow cytometry at excitation wavelengths at
405nm and 488 nm. The excitation fluorescence at 405
nm increases while the excitation at 488 nm decreases
when the probe is oxidized. The ratio between 405 and
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protein expression within cells. Both cell types displayed
similar levels of cytosolic roGFP oxidation but the osteo-
cytes displayed a slightly elevated mitochondrial roGFP
oxidation (Figure 6a and 6b). This is consistent with
higher oxygen consumption and mitochondrial membrane
potential in osteocytes (Figure 2). Interestingly, depletion
of glutathione by PEITC or BSO did not selectively induce
cell death in MYC-dependent osteogenic sarcoma cells
(Figure 6c and 6d). However, diminishing mitochondrial
ROS levels by using a mitochondrial-targeted vitamin E
(MVE) in MYC-dependent osteogenic sarcoma cells did
decrease cell proliferation (Figure 6e and 6f ). MVE is
targeted to mitochondria by covalently coupling the
vitamin E moiety to a triphenylphosphonium cation
(TPP), which is used as control [30,31]. TPP is a
cation that is rapidly taken up into the mitochondrial
matrix due to the negative mitochondrial membrane
potential. MVE induced cell death in the osteogenic
sarcoma cells compared to the control TPP compound
(Figure 6g). MVE significantly diminished ROS levels but
did not cause significant cell death in the differen-
tiated osteocytes compared to the control TPP com-
pound (Figure 6e and 6g). These data demonstrate
that mitochondrial ROS are critical for proliferation
and survival of MYC cancer cells.
Conclusions
MYC’s regulation of cellular metabolism in a cell-
autonomous manner has been primarily elucidated by
using immortalized proliferating cells with inducible
expression of MYC, mitogenic stimulation of quiescent
primary fibroblasts or by utilizing naive T cells isolated
from wild-type or c-MYC null mice. However, the meta-
bolic differences between isogenic MYC-dependent cancer
cells and their differentiated counterparts have not been
studied. Furthermore, the metabolic transitions that
accompany exit from the cell cycle have only rarely been
evaluated. Our present results indicate that MYC-
dependent osteosarcoma cells are dependent on glucose
metabolism through glycolysis for survival compared to
osteocytes, their differentiated counterparts. Glutamine-
induced mitochondrial respiration is necessary for cell
proliferation and survival of MYC-dependent cancer cells
compared to their differentiated counterparts. This is
consistent with previous studies where MYC induces
glucose and glutamine-dependent metabolism to
sustain the anabolic demands due to cell proliferation.
Aminotransferases were required for glutamine to sustain
mitochondrial metabolism in MYC-dependent cancer
cells, consistent with previous findings that these enzymes
predominate over glutamate dehydrogenase in glucose-
consuming, proliferating cancer cells [32]. Interes-
tingly, the inhibition of these enzymes results in celldeath of the MYC-dependent cancer cells but not their
differentiated counterparts. We had previously shown that
oncogenic Kras-dependent cells require aminotransferases
to sustain mitochondrial metabolism and cell proliferation
[14]. Furthermore, inhibition of aminotransferases pre-
vents xenograft tumor growth of MDA-MB-231 breast
cancer cells and MYC-dependent neuroblastoma cells
[33,34]. This raises the possibility that inhibition of
aminotransferases might be an effective strategy to
inhibit MYC-dependent tumorigenesis.
Previous studies have suggested that tumor cells have
higher levels of ROS compared to normal cells. ROS, in
addition to causing genomic instability, can also increase
tumorigenesis by activating signaling pathways that
regulate cellular proliferation, angiogenesis, and metasta-
sis [35]. The higher levels of ROS in cancers cells can be
exploited as an effective selective strategy to kill tumor
cells over normal cells. The administration of agents
such as PIETC or BSO, which disable antioxidant
defense mechanisms in cells, raises ROS to intolerable
levels in cancer cells but not to normal cells which
exhibit lower basal ROS levels [27]. However, we did not
notice substantial differences in ROS levels between
MYC- dependent cancer cells and their differentiated
counterparts and PIETC or BSO did not have any selec-
tive killing of MYC-dependent cancer cells. Nevertheless,
MYC-dependent tumor cells were dependent on mito-
chondrial ROS for cell proliferation as mitochondrial
targeted antioxidant MVE drastically reduced cell prolif-
eration. While previous studies have demonstrated that
NAC is effective in reducing MYC-dependent tumori-
genesis [29], it remains to be determined whether
mitochondrial-targeted antioxidants would also prevent
tumorigenesis in vivo.
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